BACKGROUND
This study evaluates the long-term efficacy of aripiprazole compared to placebo in children with bipolar disorders.
METHOD
Outpatients aged 4 to 9 years meeting DSM-IV criteria for a bipolar disorder (I, II, not otherwise specified, cyclothymia) were eligible to receive up to 16 weeks of open-label treatment with aripiprazole (phase 1). Patients were randomized into the 72-week dou...
